# Evaluation of the Efficacy and Safety of ADL5945 Once Daily for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain

> **NCT01275755** · PHASE2 · COMPLETED · sponsor: **Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 81 (actual)

## Conditions studied

- Constipation

## Interventions

- **DRUG:** Placebo
- **DRUG:** ADL5945 0.25 mg

## Key facts

- **NCT ID:** NCT01275755
- **Lead sponsor:** Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01-19
- **Primary completion:** 2011-07-15
- **Final completion:** 2011-07-15
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2018-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01275755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01275755, "Evaluation of the Efficacy and Safety of ADL5945 Once Daily for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT01275755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*